Egg Effects on the Immunomodulatory Properties of HDL
Primary Purpose
Lipid Metabolism, Inflammation
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Whole Eggs
Egg White-Based Egg Substitute
Sponsored by

About this trial
This is an interventional basic science trial for Lipid Metabolism focused on measuring Egg, HDL, Inflammation
Eligibility Criteria
Inclusion Criteria:
- 18-35 years old
- Body mass index (BMI) < 30 kg/m2, or < 30% body fat for men and < 40% body fat for women
- Willingness to consume eggs or egg whites on a daily basis during study periods
Exclusion Criteria:
- < 18 years old; > 35 years old
- BMI ≥ 30 kg/m2, or ≥ 30% body fat for men and ≥ 40% body fat for women
- Self-reported history of diabetes mellitus, coronary heart disease, stroke, renal problems, liver disease, cancer, pregnancy or lactation, autoimmunity, chronic infections, or egg allergy
- Taking lipid-lowering medications (e.g. statins, fibrates)
- A preexisting medical condition or implanted medical device that prevents participation in bioelectrical impedance measurements of body composition
- Clinical lipid and glucose values that are highly elevated, including fasting triglycerides levels higher than 500 mg/dL, fasting glucose higher than 126 mg/dL, and plasma total cholesterol greater than 240 mg/dL
Sites / Locations
- Fairfield University
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Whole Eggs
Egg White-Based Egg Substitute
Arm Description
Outcomes
Primary Outcome Measures
Fasted HDL-cholesterol
Measurement of fasted plasma HDL-cholesterol levels (mg/dL) at the end of the run-in period, and two intervention arms.
Secondary Outcome Measures
Fasted HDL lipid composition
HDL subfractions (d = 1.063-1.21) will be isolated from plasma by ultracentrifugation collected at the end of the run-in period and two intervention arms. HDL fractions will be analyzed for glycerphospholipid (phosphatidylcholine, phosphatidylethanolamine, lysophosphatidylcholine, phosphatidylinositol) and sphingolipid (sphingomyelin) composition by mass spectrometry. Each lipid class will be presented as a percent (%) of total HDL lipids.
Cholesterol-accepting capacity of serum
The cholesterol efflux from macrophages to subject serum will be measured at the end of the egg-free run-in period and both intervention periods using a fluorescent cholesterol efflux kit. Results will be expressed as % cholesterol efflux, calculated as (fluorescence intensity of media/[fluorescent intensity of cell lysates + media]) x 100.
Inflammatory potential of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) will be isolated at the end of the egg-free run-in period and both intervention periods. PBMCs will be cultured ex vivo and stimulated with lipopolysaccharide. Media will be collected to measure tumor necrosis factor alpha concentrations (pg/mL) in cell media.
Full Information
NCT ID
NCT03577223
First Posted
June 15, 2018
Last Updated
May 26, 2021
Sponsor
Fairfield University
Collaborators
United States Department of Agriculture (USDA)
1. Study Identification
Unique Protocol Identification Number
NCT03577223
Brief Title
Egg Effects on the Immunomodulatory Properties of HDL
Official Title
Egg Effects on the Immunomodulatory Properties of HDL
Study Type
Interventional
2. Study Status
Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
September 7, 2018 (Actual)
Primary Completion Date
May 15, 2019 (Actual)
Study Completion Date
May 15, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fairfield University
Collaborators
United States Department of Agriculture (USDA)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
The purpose of this study is to investigate the effects of egg intake on markers of HDL function and immune inflammation in healthy adults.
Detailed Description
28 healthy men and women (age 18-35 years old) will be recruited to participate in a 16-week randomized crossover study. Upon enrollment, all subjects will enter a 4-week run-in egg-free period where they will refrain from consuming any egg-based foods (Period 1). Subjects will then enter the first intervention period, where they be randomly assigned to consume either 3 whole eggs/day or the equivalent amount of egg white-based egg substitute/day for 4 weeks (Period 2). Afterwards, subjects will enter a 4-week washout period where egg-based foods are restricted (Period 3), followed by a second intervention period, where they be assigned to the alternative whole egg- or egg white-based treatment for 4 weeks (Period 4). Subjects will come to the Department of Biology at Fairfield University every two weeks to check-in, and to pick up their egg products during the intervention periods. Subjects will be asked to maintain their normal diet and physical activity practices throughout all periods of the study. Subjects will complete 5-day dietary records and physical activity logs at the end of each study period.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lipid Metabolism, Inflammation
Keywords
Egg, HDL, Inflammation
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Whole Eggs
Arm Type
Experimental
Arm Title
Egg White-Based Egg Substitute
Arm Type
Active Comparator
Intervention Type
Other
Intervention Name(s)
Whole Eggs
Intervention Description
3 whole eggs per day for 4 weeks
Intervention Type
Other
Intervention Name(s)
Egg White-Based Egg Substitute
Intervention Description
3-egg equivalent of egg white-based egg substitute per day for 4 weeks
Primary Outcome Measure Information:
Title
Fasted HDL-cholesterol
Description
Measurement of fasted plasma HDL-cholesterol levels (mg/dL) at the end of the run-in period, and two intervention arms.
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Fasted HDL lipid composition
Description
HDL subfractions (d = 1.063-1.21) will be isolated from plasma by ultracentrifugation collected at the end of the run-in period and two intervention arms. HDL fractions will be analyzed for glycerphospholipid (phosphatidylcholine, phosphatidylethanolamine, lysophosphatidylcholine, phosphatidylinositol) and sphingolipid (sphingomyelin) composition by mass spectrometry. Each lipid class will be presented as a percent (%) of total HDL lipids.
Time Frame
16 weeks
Title
Cholesterol-accepting capacity of serum
Description
The cholesterol efflux from macrophages to subject serum will be measured at the end of the egg-free run-in period and both intervention periods using a fluorescent cholesterol efflux kit. Results will be expressed as % cholesterol efflux, calculated as (fluorescence intensity of media/[fluorescent intensity of cell lysates + media]) x 100.
Time Frame
16 weeks
Title
Inflammatory potential of peripheral blood mononuclear cells
Description
Peripheral blood mononuclear cells (PBMCs) will be isolated at the end of the egg-free run-in period and both intervention periods. PBMCs will be cultured ex vivo and stimulated with lipopolysaccharide. Media will be collected to measure tumor necrosis factor alpha concentrations (pg/mL) in cell media.
Time Frame
16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
18-35 years old
Body mass index (BMI) < 30 kg/m2, or < 30% body fat for men and < 40% body fat for women
Willingness to consume eggs or egg whites on a daily basis during study periods
Exclusion Criteria:
< 18 years old; > 35 years old
BMI ≥ 30 kg/m2, or ≥ 30% body fat for men and ≥ 40% body fat for women
Self-reported history of diabetes mellitus, coronary heart disease, stroke, renal problems, liver disease, cancer, pregnancy or lactation, autoimmunity, chronic infections, or egg allergy
Taking lipid-lowering medications (e.g. statins, fibrates)
A preexisting medical condition or implanted medical device that prevents participation in bioelectrical impedance measurements of body composition
Clinical lipid and glucose values that are highly elevated, including fasting triglycerides levels higher than 500 mg/dL, fasting glucose higher than 126 mg/dL, and plasma total cholesterol greater than 240 mg/dL
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Catherine J Andersen, PhD, RD
Organizational Affiliation
Fairfield University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fairfield University
City
Fairfield
State/Province
Connecticut
ZIP/Postal Code
06824
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Egg Effects on the Immunomodulatory Properties of HDL
We'll reach out to this number within 24 hrs